Nitroxoline - Asieris Pharmaceuticals
Alternative Names: APL-1202; VesiqueLatest Information Update: 14 Jun 2025
At a glance
- Originator Johns Hopkins University
- Developer Asieris Pharmaceuticals
- Class Antibacterials; Antifungals; Antineoplastics; Antiprotozoals; Hydroxyquinolines; Nitroquinolines; Small molecules
- Mechanism of Action Methionine aminopeptidase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Bladder cancer
- Phase I Amoebiasis
- No development reported Prostate cancer
Most Recent Events
- 18 Apr 2025 Efficacy data from phase-I/II ANTICIPATE trail in Bladder cancer released by Asieris Pharmaceuticals
- 31 Jan 2025 Syneos Health terminates phase I trial in for Healthy volunteers in Australia due to a business decision and development strategy (PO, Tablet) (NCT06435039)
- 06 Jan 2025 Asieris and CDC submits IND application to US FDA for expanded-access trial